Synthesis,structure and in vitro anticancer activity of ruthenium(II) and platinum(II) complexes with chiral aminophosphine ligands

Transition Metal Chemistry - (R)-[Ru(η6-p-MeC6H4iPr)Cl2{Ph2PNHCH(CH3)(C6H4-4-F)}] (1) and cis-(R,R)-[PtCl2{Ph2PNHCH(CH3)(C6H4-4-F)}2] (2) have been obtained by the reaction of the chiral...     

Dinuclear versus tetranuclear cluster formation in zinc(II) nitrate/di-2-pyridyl ketone chemistry: synthetic, structural and spectroscopic studies

The use of di-2-pyridyl ketone, (py)2CO, in zinc(II) nitrate chemistry has yielded a dinuclear complex and a cationic tetranuclear cluster. The 1:1 Zn(NO3)2.4H2O/(py)2CO reaction system in EtOH gives [Zn2(NO3)2{(py)2C(OEt)O}2].0.5H2O (1.0.5H2O), whereas the same reaction system in MeCN yields [Zn4(NO3)3{(py)2C(OH)O}4(H2O)](NO3) (2). The monoanionic derivatives of the hemiacetal and the gem-diol forms of di-2-pyridyl ketone have been derived from the ZnII-mediated addition of solvent (EtOH, H2O involved in MeCN) on the carbonyl group of (py)2CO. Each (py)2C(OEt)O- ion functions as an eta1:eta2:eta1:mu2 ligand in 1.0.5H2O chelating the two ZnII atoms through the 2-pyridyl nitrogen atoms and the common bridging, deprotonated oxygen atom; one asymmetric chelating nitrate completes six coordination at each metal center. The tetranuclear cluster cation of 2 has a cubane topology with the ZnII ions and the deprotonated oxygen atoms from the four eta1:eta3:eta1:mu3 (py)2C(OH)O- ligands occupying alternate vertices. Three monodentate nitrates and one aqua ligand complete the sixth coordination site at the metal ions. The two complexes have been characterized by IR and far-IR spectroscopies. Characteristic bands are discussed in terms of the known structures and the coordination modes of the nitrato ligands. Upon excitation at 371 nm, complex 2 displays blue photoluminescence in the solid state at room temperature with two emission maxima at 430 and 455 nm.     

Novel complexes of tris(aminomethyl)phosphanes with platinum(II): Structural, spectroscopic, DFT and biological activity studies

Two new platinum(II) complexes with tris(aminomethyl)phosphanes: [trans-PtCl₂{P(CH₂N(CH₂CH₂)₂NCH₃)₃}₂] (1Pt) and [trans-PtCl₂{P(CH₂N(CH₂CH₂)₂O)₃}₂] (2Pt) were prepared and characterized with NMR and UV-Vis spectroscopies. Their structures were investigated by X-ray crystallography and DFT methods. TDDFT calculations were employed to interpret the electronic spectra of the complexes. Obtained results are not unequivocal, however population analysis indicate, that the character of HOMO and HOMO−1 orbitals depend strongly on the electron donoring properties of the phosphane ligand. Biological activity of 2Pt complex, which is more stable and more soluble in polar solvents than 1Pt, was examined in vitro on the Vero cell line (IC₅₀ = 12.5 μM). At higher concentrations it induces apoptosis, probably due to changes of the cell cytoskeleton. Luminescence quenching studies and CD spectroscopy of interactions of 2Pt with HSA and BSA indicate that these albumins bind the complex slightly - without altering their tertiary structures, however HSA interacts with 2Pt noticeably stronger than BSA. It was also found that 2Pt does not cleave supercoiled pUC18 plasmid.     

Preparation, characterization and in vitro anticancer activity of platinum(II) complexes with N-Cyclohexyl-1,3-propanediamine as the carrier

New JM118 (active form of satraplatin) analogues with N-cyclohexyl-1,3-propanediamine (N-chpda) as the carrier, cis-[Pt(N-chpda)X2] (X2=2Cl(-) (1), oxalate (2), malonate (3), 1,1-cyclobutanedicarboxylate (CBDCA) (3), and 3-hydroxy-1,1-cyclobutanedicarboxylate(HO-CBDCA) (4)), have been synthesized and characterized by elemental analysis and spectroscopic data along with X-ray crystal structure for a representative compound cis-[Pt(N-chpda)Cl2]. The complexes have also been evaluated for their in vitro anticancer activity. All these analytical data are in good agreement with the structures of the desired compounds. The Pt(II) is in a square planar environment and is coordinated by a chelating N-chpda ligand and 2Cl(-) in cis position, and there are two crystallographically independent cis-[Pt(N-chpda)Cl2] molecules linked together by intermolecular N-H...Cl hydrogen bonds. Compounds 1 and 2 are very active against human lung cancer cell line (AGZY) and human lymphocytic leukemia cell line (Raji), and are much more active than carboplatin. Platinum(II) complexes with N-cyclohexyl-1,3-propanediamine is an alternative choice for mixed ammine/aminoplatinum anticancer drugs.     

Novel copper(II) heterochelate: synthesis,structural features and fluorescence studies

Fluorescence properties of four based derivatives [Aⁿ] (where n = 1–4) and their Cu(II) heterochelates of the type [Cu(Aⁿ)(CQ)(OH)]^?xH₂O {where A¹ = 3‐(2‐oxo‐2H‐chromen‐3‐yl)‐4H‐furo[3,2‐c]chromen‐4‐one, A² = 8‐methyl‐3‐(2‐oxo‐2H‐chromen‐3‐yl)‐4H‐furo[3,2‐c]chromen‐4‐one, A³ = 6‐methyl‐3‐(2‐oxo‐2H‐chromen‐3‐yl)‐4H‐furo[3,2‐c]chromen‐4‐one, A⁴ = 8‐chloro‐3‐(2‐oxo‐2H‐chromen‐3‐yl)‐4H‐furo[3,2‐c]chromen‐4‐one and x = 3, 2, 4, 1} were studied at room temperature. The fluorescence spectra of heterochelates show red shift, which may be due to the chelation by the ligands to the metal ion. It enhances ligand ability to accept electrons and decreases the electron transition energy. The kinetic parameters such as order of reaction (n), energy of activation (E_a), entropy (ΔS^#), pre‐exponential factor (A), enthalpy (ΔH^#) and Gibbs free energy (ΔG^#) have been reported. The antimicrobial activity of Clioquinol and Cu(II) heterochelates have been determined and described. All the heterochelates showed a more effective antimicrobial activity than the free ligand. Copyright © 2010 John Wiley & Sons, Ltd.     

Phosphino-aminothiazoline platinum(II) and platinum(II)/gold(I) complexes: structural, chemical and vapoluminescent properties

Phosphino-amino-thiazolines and -thiazoles can exist in solution in two tautomeric forms, in which the N-H proton involves the endo-cyclic or exo-cyclic nitrogen atom. The two tautomers show different reactivities toward alcoholysis; the imino form degrades more rapidly. Their bischelated platinum complexes were studied in the solid state by single crystal X-ray diffraction. Thus, the unique stereoelectronic features of the [Pt(PN(th))] (PN(th)=diphenylposphino-aminothiazoline) moiety were revealed. The complex cis-[Pt(PN(th))(2)] reacts with gold(I) salts to yield dimetallic compounds, the molecular structures of which have been determined by X-ray diffraction. Solid cis-[Pt(PN(th))(2)] shows vapoluminescent properties if exposed to alcohol vapors. A combined photophysical and crystallographic investigation has been carried out to clarify the unprecedented rigidochromic role of the alcohol in this phenomenon.     

Novel platinum(II)-based anticancer complexes and molecular hosts as their drug delivery vehicles

Platinum(II)-based DNA intercalators where the intercalating ligand is 1,10-phenanthroline or a phenanthroline derivative and where the ancillary ligand is either achiral (e.g. ethylenediamine) or chiral (e.g. diaminocyclohexane) show a range of cytotoxicities with a defined structure-activity relationship. The most cytotoxic are those that contain methylated-phenanthroline ligands and 1S,2S-diaminocyclohexane (S,S-dach) as the ancillary ligand. We have developed a new purification method using Sep-Pak C-18 reverse phase columns, which means these metal complexes can be made faster and cheaper compared to published methods. Platinum(II)-based complexes containing imidazole, pyrrole and beta-alanine subunits, that are capable of recognising specific DNA base-pair sequences have also been synthesised. These include linear or hairpin polyamide ligands that can recognise DNA sequences up to seven base-pairs in length and contain single platinum centres capable of forming monofunctional adducts with DNA. We have now synthesised and characterised, by (1)H and (195)Pt NMR, ESI-MS and elemental analysis, the first dinuclear platinum(II) DNA sequence selective agent. Finally, using (1)H NMR we have examined the encapsulation of our platinum(II)-based DNA intercalators by cucurbit[6]uril (CB[6]). Encapsulation by CB[6] was found to not significantly change the cytotoxicity of five platinum(II)-based DNA intercalators, indicating it may have utility as a molecular carrier for improved drug delivery.     

Manganese(II) complexes of substituted di-2-pyridyl ketone thiosemicarbazones: structural and spectral studies

The reaction between manganese(II) acetate and two substituted thiosemicarbazones derived from di-2-pyridyl ketone (HL) in 1:2 molar ratio produces new complexes of general formula [MnL2]. The thiosemicarbazone moiety in HL deprotonates and gets coordinated to Mn(II) through the azomethine nitrogen, one of the pyridyl nitrogens, and the thiolate sulfur in both the complexes. The crystal structure of [MnL2(1)] was established by single crystal X-ray diffraction and the compound crystallizes into a monoclinic lattice with P2(1)/c space group. Manganese(II) exists in a distorted octahedral geometry in the complexes.     

Palladium(II) and platinum(II) complexes with tridentate iminophosphine ligands; synthesis and structural studies

The previously synthesised Schiff-base ligands 2-(2-Ph(2)PC(6)H(4)N[double bond, length as m-dash]CH)-R'-C(6)H(3)OH (R'= 3-OCH(3), HL(1); 5-OCH(3), HL(2); 5-Br, HL(3); 5-Cl, HL(4)) were prepared by a faster, more efficient route involving a microwave assisted co-condensation of 2-(diphenylphosphino)aniline with the appropriate substituted salicylaldehyde. HL(1-4) react directly with M(II)Cl(2)(M = Pd, Pt) or Pt(II)I(2)(cod) affording neutral square-planar complexes of general formula [M(II)Cl(eta(3)-L(1-4))](M = Pd, Pt, 1-8) and [Pt(II)I(eta(3)-L(1-4))](M = Pd, Pt, 9-12). Reaction of complexes 1-4 with the triarylphosphines PR(3)(R = Ph, p-tolyl) gave the novel ionic complexes [Pd(II)(PR(3))(eta(3)-L(1-4))]ClO(4)(13-20). Substituted platinum complexes of the type [Pt(II)(PR(3))(eta(3)-L(1-4))]ClO(4)(R = P(CH(2)CH(2)CN)(3)21-24) and [Pt(II)(P(p-tolyl)(3))(eta(3)-L(3,4))]ClO(4)( 25 and 26 ) were synthesised from the appropriate [Pt(II)Cl(eta(3)-L(1-4))] complex (5-8) and PR(3). The complexes are characterised by microanalytical and spectroscopic techniques. The crystal structures of 3, 6, 10, 15, 20 and 26 were determined and revealed the metal to be in a square-planar four-coordinate environment containing a planar tridentate ligand with an O,N,P donor set together with one further atom which is trans to the central nitrogen atom.     

Traceable platinum(II) complexes with alkylene diamine-derived ligands: synthesis,characterization and in vitro studies

Diiodido- (6a/6b) and dichloridoplatinum(II) complexes (7a/7b) with fluorescent ligands 2-[(2-aminoethyl)amino]ethyl-2-(methylamino)benzoate (5a) and 2-amino-1-(aminoethyl)ethyl-2-(methylamino)benzoate (5b) were prepared and characterized by elemental analysis, ESI-MS analysis, fluorescence spectrometry, as well as ¹H, ¹³C, and ¹⁹⁵Pt NMR spectroscopy. All compounds have been tested against A2780 ovarian cancer, A549 lung carcinoma, and HT-29 colon cancer cell lines using sulforhodamine-B assay. The activity increased from ligand precursors, diiodido- to dichloridoplatinum(II) complexes, except against HT-29 cell line where diiodido and dichlorido expressed similar activity. These compounds enter the tumor cells and emit a bright fluorescence at ca. 470 nm, mainly targeting nuclei.     

Synthesis of di-, tri- and tetranuclear platinum(II) and copper(I) acetylide complexes

Heterobimetallic {cis-[Pt](μ-σ,π-CCPh)₂}[Cu(NCMe)]BF₄ (3a: [Pt] = (bipy)Pt, bipy = 2,2′-bipyridine; 3b: [Pt] = (bipy′)Pt, bipy′ = 4,4′-dimethyl-2,2′-bipyridine) is accessible by the reaction of cis-[Pt](CCPh)₂ (1a: [Pt] = (bipy)Pt, 1b: [Pt] = (bipy′)Pt]) with [Cu(NCMe)₄]BF₄ (2). Substitution of NCMe by PPh₃ (4) can be realized by the reaction of 3a with 4, whereby [{cis-[Pt](μ-σ,π-CCPh)₂}Cu(PPh₃)]BF₄ (5) is formed. On prolonged stirring of 3 and 5, respectively, NCMe and PPh₃ are eliminated and tetrametallic {[{cis-[Pt](η²-CCPh)₂}Cu]₂}(BF₄)₂ (6) is produced. Addition of an excess of NCMe to 6 gives heterobimetallic 3a.When instead of NCMe or PPh₃ chelating molecules such as bipy (7) are reacted with 3a then the heterobimetallic π-tweezer molecule [{cis-[Pt](μ-σ,π-CCPh)₂}Cu(bipy)]BF₄ (8) is formed. Treatment of 8 with another equivalent of 7 produced [Cu(bipy₂)]BF₄ (9) along with [Pt](CCPh)₂. However, when 3b is reacted with 1b in a 1:1 molar ratio then 10 and 11 of general composition [{[Pt](CCPh)₂}₂Cu]BF₄ are formed. These species are isomers and only differ in the binding of the PhCC units to copper(I). A possible mechanism for the formation of 10 and 11 is presented.The solid state structures of 6, 10 and 11 are reported. In 11 the [{cis-[Pt](μ-σ,π-CCPh)₂}₂Cu]⁺ building block is set-up by two nearly orthogonal positioned bis(alkynyl) platinum units which are connected by a Cu(I) ion, whereby the four carbon-carbon triple bonds are unsymmetrical coordinated to Cu(I). In trimetallic 10 two cis-[Pt](CCPh)₂ units are bridged by a copper(I) center, however, only one of the two PhCC ligands of individual cis-[Pt](CCPh)₂ fragments is η²-coordinated to Cu(I) giving rise to the formation of a [(η²-CCPh)₂Cu]⁺ moiety with a linear alkyne-copper-alkyne arrangement (alkyne = midpoint of the CC triple bond). In 6 two almost parallel oriented [Pt](CCPh)₂ planes are linked by two copper(I) ions, whereby two individual PhCC units, one associated with each Pt building block, are symmetrically π-coordinated to Cu.     

Fluorophenylantimony carboxylates(II): synthetic and spectroscopic studies (UV, IR, H, F and C NMR) of pentafluorophenylantimony(V) di- and tetracarboxylates

Pentafluorophenylantimony(V) di- and tetracarboxylates of the molecular formula C₆F₅SbX₂L₂ (when X=L=OCOR (R=CH₃, CH₂Cl, CHCl₂, CCl₃, CF₃, CH₂OC₆H₃Cl₂-2,4, CH₂OC₆H₂Cl₃-2,4,5) and when X=Cl; L=OCOCH_3, OCOCHCl₂) have been synthesized by the metathetical reaction of pentafluorophenylantimony(V) tetrachloride and (dibromide)dichloride with corresponding sodium salt of carboxylic acids in appropriate molar ratio using 15-crown-5 as phase transfer catalyst. The van’t Hoff factor ‘i’ and molar conductance data of the compounds revealed them to be monomeric and non-conducting in nature. Elemental analysis, UV, IR and NMR (¹H, ¹⁹F and ¹³C) were used to characterize the derivatives. Compounds are tentatively assigned as a pentacoordinated square pyramidal structure in which carboxylate ligand behaving as a monodentate ligand.     

Copper(II)-activated transformation of azomethine to imidate: synthetic and structural studies

The Schiff base 2-pyridine–carboxaldehyde 4-dimethylaminobenzoylhydrazone (HL, 1) was prepared by reacting 2-pyridine–carboxaldehyde and 4-dimethylaminobenzoylhydrazine in a 1:1 molar ratio in methanol. Reaction of HL (1) with Cu(O₂CCH₃)₂·H₂O (in a 1:1 molar ratio) in methanol afforded a dinuclear copper(II) complex, [Cu₂(μ-O₂CCH₃)₂L′₂]·2H₂O (2). The azomethine functionality (---CH=N---) of 1 is converted to imidate (---C(OMe)=N---) in the complexed ligand L′⁻. Molecular structures of both 1 and 2 were determined by X-ray crystallographic studies. The dinuclear molecule of 2 is centrosymmetric and contains two monoatomic bridging acetate groups. Each copper(II) centre is in a square-pyramidal N₂O₃ coordination sphere. The ligand, L′⁻ coordinates the metal ion via the pyridine-N, the imidate-N, and the deprotonated amide-O atoms. One of the acetate oxygen atoms completes the N₂O₂ square-plane. The oxygen of the symmetry-related acetate fills the apical coordination site. Structural parameters are consistent with both copper ions being in a +2 oxidation state. The room temperature magnetic moment is 1.89 μ_B (per Cu). In powder phase the complex displays an axial EPR spectrum at 298 K. The complex is nonconducting in methanol solution. The electronic spectrum shows a ligand field absorption at 680 nm and charge transfer bands in the range 426–215 nm.     

Gold(I) chloride adducts of 1,3-bis(di-2-pyridylphosphino)propane: synthesis, structural studies and antitumour activity

The novel water soluble bidentate phosphine ligand 1,3-bis(di-2-pyridylphosphino)propane (d2pypp) has been synthesized by a convenient route involving treatment of 2-pyridyllithium with Cl(2)P(CH(2))(3)PCl(2) and isolation in crystalline form as the hydrochloride salt. The synthesis of the precursor Cl(2)P(CH(2))(3)PCl(2) has been optimized by the use of triphosgene as the chlorinating agent. The 2 : 1 and 1 : 2 AuCl : d2pypp adducts have been synthesized and characterized by NMR spectroscopy and single crystal X-ray studies, and shown to be of the form (AuCl)(2)(mu-d2pypp-P,P') and [Au(d2pypp-P,P')(2)]Cl(.3.75H(2)O), respectively. The latter is more lipophilic than analogous 1 : 2 adducts of gold(I) chloride with the diphosphine ligands 1,2-bis(di-n-pyridylphosphino)ethane (dnpype) for n = 2, 3 and 4, based on measurement of the n-octanol-water partition coefficient (log P = -0.46). A single crystal structure determination of the 1 : 2 Au(I) complex of the 3-pyridyl ethane ligand shows it to be of the form [Au(d3pype-P,P')(2)]Cl.5H(2)O. The in vitro cytotoxic activity of [Au(d2pypp)(2)]Cl was assessed in human normal and cancer breast cells and selective toxicity to the cancer cells found. The significance of these results to the antitumour properties of chelated 1 : 2 Au(I) diphosphine complexes is discussed.     

Coordination of di- and triimine ligands at ruthenium(II) and ruthenium(III) centers: structural,electrochemical and radical scavenging studies

Herein, we explore the coordination of di- and triimine chelators at ruthenium(II) and ruthenium(III) centers. The reactions of 2,6-bis-((4-tetrahydropyranimino)methyl)pyridine (thppy), N¹,N²-bis((3-chromone)methylene)benzene-1,2-diamine (chb), and tris-((1H-pyrrol-2-ylmethylene)ethane)amine (H₃pym) with trans-[Ru^IICl₂(PPh₃)₃] afforded the diamagnetic ruthenium(II) complex cis-[RuCl₂(thppy)(PPh₃)] (1) and the paramagnetic complexes [mer-Ru₂(μ-chb)Cl₆(PPh₃)₂] (2), and [Ru(pym)] (3), respectively. The complexes were characterized by IR, NMR, and UV–vis spectroscopy and molar conductivity measurements. The structures were confirmed by single crystal X-ray diffraction studies. The redox properties of the metal complexes were probed via cyclic- and squarewave voltammetry. Finally, the radical scavenging capabilities of the metal complexes towards the NO and 2,2-di(4-tert-octylphenyl)-1-picrylhydrazyl (DPPH) radicals were investigated     

Novel bis(thiosemicarbazones) of the 3,5-diacetyl-1,2,4-triazol series and their platinum(II) complexes: chemistry, antiproliferative activity and preliminary nephrotoxicity studies

The preparation and characterization of three novel (4)N-monosubstituted bis(thiosemicarbazone) ligands of 3,5-diacetyl-1,2,4-triazol series and their dinuclear platinum complexes are described. The crystal and molecular structure of the [Pt(μ-H(3)L(3))](2) complex derived of 3,5-diacetyl-1,2,4-triazol bis((4)N-p-tolylthiosemicarbazone), H(5)L(3), has been resolved by single crystal X-ray diffraction. The ligands coordinate, in an asymmetric dideprotonate form, to the platinum ions in a tridentate fashion (NNS) and S-bridging bonding modes. Thus the molecular units of the platinum complexes are stacked as dimers. The new compounds synthesized have been evaluated for antiproliferative activity in vitro against NCI-H460, A2780 and A2780cisR human cancer cell lines. The cytotoxicity data suggest that these compounds may be endowed with important antitumour properties since are capable of not only circumventing cisplatin resistance in A2780cisR cells but also exhibit high antiproliferative activity in human non-small cell lung cancer NCI-H460 cells. The interactions of these compounds with calf thymus DNA was investigated by UV-vis absorption and a nephrotoxic study, in LLC-PK1 cells, has also been carried out.     

Synthesis, characterisation and in vitro evaluation of palladium(II) iminophosphine complexes for anticancer activity

Palladium(II) complexes have been obtained from the reactions of the iminophosphine ligands, (L1–L7), respectively, with [PdCl₂(COD)] and [PdMeCl(COD)] in CH₂Cl₂ at room temperature. The palladium(II) complexes were characterised using elemental analysis, electro spray ionisation–mass spectrometry (ESI–MS), NMR (¹H and ³¹P), IR spectroscopy and X-ray diffraction studies. Single-crystal X-ray diffraction analysis for complexes 2, 7 and 8 revealed that the complexes exhibited a slightly distorted square planar geometry. In vitro cytotoxic study results show that the palladium complexes exhibit moderate activity and block the proliferation of WHCO1 cells with an IC₅₀ range of 19.02–45.27 μM, and IC₅₀ range of 10.03–68.54 μM for the KYSE450 cell lines.     

Heteroleptic Pd(II) dithiocarbamates: synthesis,characterization, packing and in vitro anticancer activity against HeLa cell line

Two new heteroleptic Pd(II) dithiocarbamates (1 and 2) have been synthesized by reaction of equimolar quantities of palladium(II) chloride, sodium 4-(3-methoxyphenyl)piperazine-1-carbodithioate, and appropriate substituted triphenylphosphines. The synthesized complexes have been characterized by their physical, spectral (IR, ¹H, ¹³C, and ³¹P NMR), and X-ray crystallographic data. Complexes 1 and 2 showed square-planar geometry both in solution and solid states. The crystal packing of both complexes revealed similar 3-D-supramolecular networks comprised of 1-D chains. However, the nature and strength of various non-covalent interactions of these networks were slightly different. The DNA interaction studies of the complexes have been carried out by UV–visible spectroscopy to evaluate their anticancer potential. The study suggested intercalative interaction with 2.402 × 10⁴ and 2.713 × 10³ M^?1 binding constants, respectively. The complexes have also been evaluated for their anticancer activity against HeLa cell line. Both complexes showed higher activity with IC₅₀ values much lower (22.176 and 26.166 μM for 1 and 2, respectively) than the standard cisplatin (78.075 μM). Furthermore, the complexes induced stronger DNA fragmentation as investigated by DNA ladder assay for apoptosis. Our findings suggested that the anticancer action of these compounds stems from their interaction with DNA leading to DNA damage and apoptosis. The excellent activity of 1 and 2 deserves to be a focus for further research and in vivo studies.